Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667202 | 0.88 | GPR119 (0.49) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL24847099 | 0.86 | LMNA (0.48) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL29086746 | 0.86 | MEN1 (0.53) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2445935 | 0.84 | GPR119 (0.49) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL6846616 | 0.84 | MEN1 (0.47) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL5383294 | 0.83 | NR1H2 (0.54) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL29569426 | 0.83 | NR1H2 (0.54) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL24429829 | 0.83 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1LMNAALDH1A1 | |
| SCHEMBL18755012 | 0.82 | NR1H2 (0.41) | NR1H2GPR119 | |
| SCHEMBL20874110 | 0.81 | MAPT (0.65) | LMNAALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | SMARCA2 1039/4885SMARCA4 800/4885PBRM1 1273/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | SMARCA2 1892/4885SMARCA4 1473/4885PBRM1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.